|
|
Volumn 7 Suppl 1, Issue , 2006, Pages
|
|
Treatment of diffuse large B-cell lymphoma: a risk-based approach.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CHOP PROTOCOL;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
MONOCLONAL ANTIBODY;
PREDNISONE;
RITUXIMAB;
VINCRISTINE;
B CELL LYMPHOMA;
CLINICAL TRIAL;
DRUG THERAPY;
HISTIOCYTIC LYMPHOMA;
HUMAN;
IMMUNOTHERAPY;
LYMPHOSARCOMA;
METHODOLOGY;
POSITRON EMISSION TOMOGRAPHY;
PROGNOSIS;
REVIEW;
RISK;
TIME;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
DRUG THERAPY;
HUMANS;
IMMUNOTHERAPY;
LYMPHOMA, B-CELL;
LYMPHOMA, DIFFUSE;
LYMPHOMA, LARGE-CELL;
POSITRON-EMISSION TOMOGRAPHY;
PREDNISONE;
PROGNOSIS;
RISK;
TIME FACTORS;
TREATMENT OUTCOME;
VINCRISTINE;
MLCS;
MLOWN;
|
|
EID: 39049178753
PISSN: 15579190
EISSN: None
Source Type: Journal
DOI: 10.3816/CLM.2006.s.003 Document Type: Article |
|
Times cited : (3)
|
|
References (47)
|
